ArticleScientific reports2023
A buprenorphine depot formulation provides effective sustained post-surgical analgesia for 72 h in mouse femoral fracture models.
Article in Scientific reports, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 18 citations in OpenAlex.
- Evaluation of a human slow-release buprenorphine formulation in rats - tactile sensitivity and plasma concentration.Laboratory animal research · 2026Article
- Carprofen and buprenorphine delivery using micropipette-guided drug administration (MDA) in mice.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2026Article
- Advancing the 3Rs in bone tissue engineering: emergingFrontiers in physiology · 2026Review
- Erythroid precursors regulate local oxygen tension and repair outcomes in the bone marrow niche.Proceedings of the National Academy of Sciences of the United States of America · 2025Article
- Review
- Erythroid precursors regulate local oxygen tension and repair outcomes in the bone marrow niche.bioRxiv : the preprint server for biology · 2025Article
- CYR61 delivery promotes angiogenesis during bone fracture repair.NPJ Regenerative medicine · 2025Article
- Buprenorphine and cannabidiol co-administration reduces survival in a mouse model of orthopedic trauma.Frontiers in pharmacology · 2025Article
- Article
- Deep behavioral phenotyping tracks functional recovery following tibia fracture in mice.Frontiers in physiology · 2025Article
- Refining pain management in mice by comparing multimodal analgesia and NSAID monotherapy for neurosurgical procedures.Scientific reports · 2024Article
- Development, Validation and Characterization of a Novel Portable Closed Fracture Device.In vivo (Athens, Greece)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 8 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Adequate pain management is essential for ethical and scientific reasons in animal experiments and should completely cover the period of expected pain without the need for frequent re-application. However, current depot formulations of Buprenorphine are only available in the USA and have limited duration of action. Recently, a new microparticulate Buprenorphine formulation (BUP-Depot) for sustained release has been developed as a potential future alternative to standard formulations available in Europe. Pharmacokinetics indicate a possible effectiveness for about 72 h. Here, we investigated whether the administration of the BUP-Depot ensures continuous and sufficient analgesia in two mouse fracture models (femoral osteotomy) and could, therefore, serve as a potent alternative to the application of Tramadol via the drinking water. Both protocols were examined for analgesic effectiveness, side effects on experimental readout, and effects on fracture healing outcomes in male and female C57BL/6N mice. The BUP-Depot provided effective analgesia for 72 h, comparable to the effectiveness of Tramadol in the drinking water. Fracture healing outcome was not different between analgesic regimes. The availability of a Buprenorphine depot formulation for rodents in Europe would be a beneficial addition for extended pain relief in mice, thereby increasing animal welfare.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.